2021 Virtual Annual Scientific Meeting
On Demand Poster Presentations by Category

Basic Science

Safety Evaluation of Fremanezumab in Nonclinical Developmental and Reproductive Toxicology (DART) Studies in Rats and Rabbits
Maya Sokolovsky, MSc

Clinical Presentation/Diagnosis

Expert Consensus on the Benefits and Limitations of the Diagnostic Criteria for Post-Traumatic Headache as Defined by the International Classification of Headache Disorders-3rd Edition
Emily Schlitz-Fortenberry, MD
Erafat Rehim, MD

Overt Ergotism Due to Overuse of Ergotamine-caffeine
FRANCIS M V, MBBS, MS

Neuroocular Migraine*
*Not CME Eligible
Merrick Reynolds

Overt Ergotism Due to Overuse of Ergotamine-caffeine
Erafat Rehim, MD

Nutcracker Phenomenon with Headache as the Predominant Symptom: A Unique New Daily Persistent Headache Subtype?
Todd Rozen, MD

Paroxysmal Hemicrania: Case Series Presenting in an Orofacial Pain Clinic
Anas Al-Taee, DDS

Pachymeningeal Enhancement in an Atypical Presentation of Giant Cell Arteritis
Ayesha Ahmad, MD

Childhood Variant Intermittent Angle Closure: A Treatable Pediatric Headache of Ophthalmic Etiology
Grant Slagle, DO

New Onset Cluster Headache, Triggered by COVID?
Michael Yang, MD

The Relationship Between Perceived Stress and Peak Pain Severity in Individuals with Chronic Migraine: A Longitudinal Cohort Study Using Daily Prospective Diary Data*
*Not CME Eligible
Serena Orr, MD, MSc

Cervical Dystonia Associated with Post-Traumatic Chronic Migraine
Matthew Kozminski, DO, FAHS

Important Factors Associated with Hesitating to Consult for Migraine Care: Results of the OVERCOME (US) Study
Michael Reed, PhD

Allodynia and Headache Related to Personal Protective Equipment to Prevent COVID-19
Karen Ferreira, PhD

The Role of a Potential Biomarker in Patients with Migraine: Review and New Insights
Karen Ferreira, PhD

Traumatic Brain Injury Temporal Lesion Causing Hemicrania Continua: A Case Report
Caitlin Christensen, MD

Relation Between Central Sensitization and Temporomandibular Disorder
Alinne Rymovicz, PhD
Questionnaire-based Evaluation of Sleep Quality in Patients with Migraine - a Case-control Study  
Rahul Sabharwal, MBBS

Interdisciplinary Care for a Refractory Vestibular Migraine Patient Through Same-day Visits with Headache Neurology, Physical Therapy, Occupational Therapy, and Pain Psychology  
Shivani Shah, DO

Delayed Secondary Intracranial Hypertension Post Mild Traumatic Brain Injury  
Lauren Green, DO

COVID-19 Related Headache Exquisite Response to Therapy  
Anvita Suneja

Single-centre Experience of Headache Phenotype in Children with Idiopathic Intracranial Hypertension  
Hiba Akbari, MBBS

Interictal Light Sensitivity in Migraineurs with Aura vs Without Aura  
Cecilia Martindale

Clinical, Psychological, and Sensory Characteristics Associated with Headache Attributable to Temporomandibular Disorder in Participants with Chronic Myofascial Temporomandibular Disorder  
Inna Tchivileva, MD, MS

Episodic Status Migrainosus: A Cross Sectional Study  
Mauricio Rueda-Sánchez, MD

Stabbing Headache Associated with Thalamic Hemorrhage: A Case Report  
Anam Baig, DO

A History of Mild Traumatic Brain Injury Is Associated with Disability and Severity of Migraine  
Ryotaro Ishii, MD, PhD

Clinical Course of Migraine During Strict Quarantine Due to SARS-Cov-2: Effect of Psychiatric Comorbidities in a Clinical Cohort  
Joe Munoz-Ceron

Lack of Effect of TBI-related Factors on Headache Occurrence in Veterans 2-15 Years After Deployment-related TBI  
James Couch, MD, PhD

Rhinologist Referral to a Headache Specialist for Non-Sinogenic Headache: A Fast Track Approach to an Interdisciplinary Collaboration  
Jyotika Singh, Do

Comorbidity of Patients with Dementia and Migraine in a Large Tertiary Academic Center  
Mason Dyess, DO

High Normal and Elevated Opening Pressures Predict Headache Improvement After Cerebrospinal Fluid Withdrawal  
Andrew Martin, MD

Hemiplegic Migraine Triggered by a Bomb Cyclone Misdiagnosed as Stroke: A Case Series  
Courtney Iser, MD

Identification of Patients with Migraine, Migraine-Related Symptoms and Migraine Medication Use Within Electronic Medical Records Using Artificial Intelligence*  
Steven Kymes, PhD, MHA

*Not CME Eligible

A Rare Case of Unilateral Facial Weakness Secondary to Perimesencephalic Non-aneurysmal Sub-arachnoid Haemorrhage!*  
Nishanth Rajanna

Relationship Between Intervals of the Menstrual Cycle and Presentation to the Emergency Department for Headache  
Crystal Jicha, MD

Dialysis- Triggered Cluster Headache: A Case Report  
Shivani Shah, DO

New Daily Persistent Headache Associated with Trisulfated Heparin Disaccharide (TS-HDS) Antibody: A Case Report  
Shivani Shah, DO

Case Report: COVID-19 Nasopharyngeal Swab Test Triggering Migraines  
Aarushi Suneja, MD

Habitus and the Brain in Pain: Influence of BMI on Migraine Patients Seen at a Large Tertiary Headache Center  
Natalia Murinova, MD

When a Peleton Ride Leads to a Nonaneurysmal Perimesencephalic Subarachnoid Hemorrhage: A Case Study  
Nicholas Koroneos, DO

Dysautonomic Manifestations in Migraine, Tension-type Headache and Cranial Neuralgias. Results from PREMECEF  
Luis Fernández-Garza

*Not CME Eligible
### Post COVID-19 Headache: A Mexican Online Survey
- Luis Fernández-Garza

### The Caffeinated Brain in Pain: Caffeine Use in Migraine Patients at a Large Tertiary Headache Center
- Natalia Murinova, MD

### Educated Brain in Pain: The Influence of Education Level on Migraine Patients Seen at a Large Tertiary Headache Center
- Natalia Murinova, MD

### Headache Associated with Personal Protective Equipment in Healthcare Workers During COVID-19 Outbreak in a Referral Centre in Mexico*
- Rogelio Dominguez-Moreno

### Vegetable, Fruits, and the Brain in Pain: Quantification of Nutrition in Migraine Patients at a Large Tertiary Headache Center
- Natalia Murinova, MD

### Case Series of Headache in Children and Adolescents with COVID-19*
- Rebecca Barmherzig, MD

### RED EAR SYNDROME AND MIGRAINE: sign or syndrome?
- Isabel Luzeiro, MD

### The role of Endolymphatic Hydrops in differentiating Vestibular Migraine from Ménière’s Disease
- Isabel Luzeiro, MD

### Vestibular migraine in children: clinical characterization of a cohort
- Isabel Luzeiro, MD

### Epidemiology

- Comorbidity of Temporomandibular Disorders in Migraine and Tension-type Headache Patients: A Systematic Review with Meta-analysis of Observational Studies
  - Paolo Bizzarri, PhD

- Psychometric Evaluation of the Activity Impairment in Migraine-Diary (AIM-D) Using Data from a Phase 3 Clinical Trial (ADVANCE) in Patients with Episodic Migraine*
  - Richard Lipton, MD

- Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine*
  - Richard Lipton, MD

- Atogepant Improved Patient-Reported Migraine-Specific Quality of Life in a 12-Week Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine*
  - Pranav Gandhi, PhD

- Predicting Treatment-response to Prescription Acute Migraine Medications
  - Ali Ezzati, MD

- Migraine Synonyms - A 5 Year Study*
  - FRANCIS M V, MBBS, MS

- Migraine and Tension-Type Headache Among Children and Adolescents: Application of International Headache Society Criteria in a Clinical Setting
  - Jacob Genizi, MD

- Cerebral Venous Thrombosis (CVT) Associated with Covid 19 Infection; A Multi-center Study
  - Sajid Hameed Shaikh, MBBS, FCPS

- Prevalence and Impact of Visual Aura in Migraine: A Population-based Study
  - Min Kyung Chu, MD, PhD

- Circadian misalignment and average headache frequency and severity in a cohort of adults with episodic migraine in Greater Boston
  - Kobina Hagan, MBChB, MPH

### Genetics
CACNA1A Mutation in Complex Patient with Hemiplegic Migraine and Bilateral Basal Ganglia Calcifications

Paul Gong, MD

Headache Education

American Headache Society National Headache Fellowship Opportunities Website Performance Review

Niushen Zhang, MD

Refractory Chronic Migraines in Patients with Mast Cell Activation Syndrome

Ana Gjurgevich, MSN

Measuring the Efficiency of an Online Migraine Management Course in Expanding Education Among Medical Professionals

Frederick Godley, MD


Anna Pace, MD

Migraine and Other Primary Headache Diagnoses and Treatment- a Knowledge and Needs Assessment of Physical Therapists

Danielle Messier, MSPT, DPT, Cert MDT


Paul Rizzoli, MD

Lasmiditan Is Effective in the Acute Treatment of Migraine in Patients with Insufficient Response to Triptans: Findings from the CENTURION Study*

John Krege, MD

*Not CME Eligible

Does Wearing off of Efficacy Occur in Galcanezumab-treated Patients at the End of the Monthly Treatment Cycle: A Post Hoc Analysis of Four Phase 3 Randomized Trials

Jessica Ailani, MD

Episodic and Chronic Cluster Headache: Evaluation of Health-related Quality of Life Impact and Estimation of Health-state Utilities*

Antje Tockhorn-Heidenreich, MSc

*Not CME Eligible

Evaluation of Cardiovascular Risks in Patients Treated with Longer-term Exposure to Galcanezumab

Richard Kovacs, MD

Knowledge and Needs of Pain Medicine Providers in Migraine Management

Jackie Yang, BS

Telehealth Headache Simulation for Nurse Practitioner Students During the COVID-19 Pandemic

Calli Cook, DNP

A Dedicated Headache Medicine Elective for Third and Fourth Year Medical Students*

Alina Masters-Israilov, MD

*Not CME Eligible

The Effect of Undergraduate Education on Headache at a Japanese Medical School: A Survey of Student Experience and Confidence

Yasushi Shibata, MD, PhD

Health Services/Outcomes Research

The Impact of the COVID-19 Pandemic on Patients with Migraine and Other Headache Disorders

Rachel Lu

Correlates of Migraine Treatment Satisfaction in a High Frequency Sample: Results from the Coalition for Headache and Migraine Patients' (CHAMP) Headache Disease Patient Access Survey*

Caroline Brooks, MA

*Not CME Eligible

What Role Do Urgent Care Centers Play in Headache Management? A Quality Improvement Study of Select Urgent Care Facilities

Dennique Khanns
The Effects of COVID-19 on Access to Telemedicine Visits in a Tertiary Headache Clinic
Aarushi Suneja, MD

Telehealth as a New Care Delivery Model: The Headache Provider Experience* Mia Minen, MD, MPH
*Not CME Eligible

Impact of and Response to the COVID-19 Pandemic on Headache Care Delivery Within the Veterans Health Administration: A National Cohort Study Jason Sico, MD, MHS

Impact of and Response to the COVID-19 Pandemic on Headache Care Delivery Within the Veterans Health Administration: A National Cohort Study Jason Sico, MD, MHS

Annual Indirect Cost Savings in Patients with Episodic or Chronic Migraine: Post-hoc Analyses from Multiple Galcanezumab Clinical Trials* Joshua Tobin, MD, FAHS
*Not CME Eligible

Comparative Study of Transcranial Doppler Parameters and Vasomotor Reactivity in People with IIH versus People with Migraine and Normal Population Vikas Lakhanpal, MD

Optimal Acute Treatment Is Associated with Productivity Gains in People with Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study Dawn Buse, PhD

Characteristics, Healthcare Utilization, and Comorbidities of People with Medically Diagnosed Migraine in the Veteran’s Health Administration: A National Cohort Study, 2008-2019 Elizabeth Seng, PhD

Study of Prescription Practices, Causes of Referral and Delay in Diagnosis of Headache by General Practitioners: A Cross-sectional Study Sulabh Tiwari, MD

Impact of Prior Monthly Headache Days on Migraine-Related Quality of Life: Results from the CaMEO Study* Dawn Buse, PhD
*Not CME Eligible

Rimegepant 75 Mg, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Applying the Benefit-Risk Method of Likelihood of Being Helped or Harmed Karissa Johnston, PhD

What Are Essential Components of Care in a Headache Center? Perspectives from Headache Neurologists Roberta Goldman, PhD

Single Center Experience of MAbs-CGRP Use for Migraine Prevention* Christopher Bondoc, MD
*Not CME Eligible

Switching Associated with Initiation of Calcitonin Gene-Related Peptide Monoclonal Antibodies versus Non-Calcitonin Gene-Related Peptide Monoclonal Antibodies Treatments for Prevention of Migraine* Richard Wenzel, PharmD
*Not CME Eligible

Leveraging Telemedicine to Improve Access to Evidence-Based Headache Care* Sara Crystal, MD
*Not CME Eligible

Real-World Safety and Efficacy of 155-195U OnabotulinumtoxinA in Participants with Chronic Migraine: Results from the REPOSE Study* Katherine Sommer, PhD
*Not CME Eligible

Functional REStoration with rEyvow (FREE): A US-based Cross-sectional Survey in Patients Taking Lasmiditan* Carrie Dougherty, MD, FAHS
*Not CME Eligible

Who Receives Novel Acute Treatments for Migraine?* Gerhardt Pohl MS, PhD
*Not CME Eligible
Adherence and Persistence Associated with Calcitonin Gene-Related Peptide Monoclonal Antibodies Compared to Non-Calcitonin Gene-Related Peptide Monoclonal Antibodies Treatments for Prevention of Migraine*

Identification of High-cost Triptan and Ergotamine-based Acute Therapies Used for Migraine in Medicaid 2019*

Assessing the Comparative Efficacy of INP104 for Acute Treatment of Migraine Attacks: A Matching-adjusted Indirect Comparison Primary Headache Disorders and Acute Medications Associated with Patients Diagnosed with Medication Overuse Headache: Analysis of US Claims Data*

Real-world Data on Reducing Migraine and Headache Days with Fremanezumab Treatment for US Patients with Chronic and Episodic Migraine: Results from a Physician Chart Review Study*

Real-world Data on Quarterly and Monthly Fremanezumab for Reducing Migraine Days and Headache Days in US Adult Patients with Migraine: Results from a Physician Chart Review Study*

Real-world Patient Characteristics, Acute Medication Use, and Treatment Patterns for Patients Initiating Fremanezumab Treatment: A US Retrospective Claims Analysis*

Real-world Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab: A US Retrospective Claims Analysis

Real-World Impact of AJOVY Use on Clinical Outcomes Among Migraine Patients with Comorbid Depression, Anxiety or Hypertension*

Patient Preferences for Self-injectable Preventive Treatments for Migraine*

Treatment Experiences in a High Frequency Sample of People with Migraine: Results of the Coalition for Headache and Migraine Patients (CHAMP) Headache Disease Patient Access Survey

Disparity Between Self-Reported and Functional Disability Among Adults with Migraine

Migraine Treatment in Pregnancy- a Knowledge and Needs Assessment of Women’s Health Care Providers

Impact of the COVID-19 Pandemic on People Living with Migraine: Results of the MICOAS Qualitative Study*

Calcitonin Gene-related Peptide (CGRP) Monoclonal Antibody (MAB) Wear-off Phenomenon in the Treatment of Migraine

Assessing Resident Opinions and Usage of Quality Measures for Headache Patients in the Resident Continuity Clinic*

Acute and Preventive Treatment Priorities Among Persons Living with Migraine: Results of the MiCOAS Qualitative Study

*Not CME Eligible

Janet Ford, MPH, PhD
Thomas O’Connell, MA
Shivang Joshi, MD, MPH, RPh
Andrew Ahn, MD, PhD
Joshua Cohen, MD, MPH, FAHS
Joshua Cohen, MD, MPH, FAHS
Dawn Buse, PhD
Dawn Buse, PhD
Krishna Tangirala, PhD
Jaein Seo, PharmD, MHS
Beth Morton, PhD
Rasha Srouji, DNP, CPNP, CNRN
Robert Shapiro, MD, PhD
Brian M. Grosberg, MD, FAHS
Dawn Buse, PhD
Maria E. Garcia-Ayala, MD
Aakash Bhargava, MD
Maya Gerstein, DRPH
Feasibility and Efficacy of Telemedicine in Patients with Chronic Headache in a Developing Country During the COVID-19 Pandemic: A Prospective Cohort Study
Sucharita Ray, MD

Real-World Outcomes of Eptinezumab
CME-certified Patient-Physician Vignette Increased Awareness of Risk Factors for Migraine Chronification and the Appropriate Use of Preventive Therapies Among Neurologists and PCPs*
Anam Baig, DO

Impact of Online-Delivered Headache Education on Community Based Pediatricians’ Confidence in Managing Primary Recurrent Headache
Marielle Kabbouche Samaha, MD

Locating Organizations and Their Methods in Registrations of Clinical Migraine Trials: Analysis of ClinicalTrials.gov
Pengfei Zhang, MD

Migraine Management with Telemedicine Visits Only: Can Patients Achieve Clinically Meaningful Improvement?*
Brad Torphy, MD

Tertiary care headache services embedded in a primary care underserved setting in Boston, MA: establishment and early experiences
Angeliki Vgontzas, MD

Imaging and Neurophysiology

A Computational Model Explores the Regulation of Cerebrospinal Fluid and Brain Tissue Sodium Levels During Migraine
Bruno Jacob, BSc, MSc

Clinical Correlates of Cross-Sectional and Longitudinal Resting State Functional Connectivity Changes of the Hypothalamus in Migraine Patients
Roberta Messina, MD

Cerebral Hemodynamics with Migraine Onset and Intervention
Samuel Grant, PhD

Other

The Visual Quality of Life in Patients with Photophobia
Amanda Redfern, MD

Physician-Assistance Algorithm for Migraine Medications
Pengfei Zhang, MD

Considerations for Treatment of Comorbid Headaches and Mast Cell Activation Syndrome: A Multidisciplinary Team Approach
Lindsey Reeves, DO

Economic Modeling of Migraine Prevention Therapies: Considerations for Current and Emerging Therapies
Karissa Johnston, PhD

Novel Acute Therapies in the Treatment of Migraine: Impact of Redosing on Cost-utility Outcomes
Karissa Johnston, PhD

Refractory Migraine Treatment During Pregnancy: A Case Report
Chelsea Stone, DO, MA

Utilization and Perceptions of Telehealth Headache Services in the Veterans Health Administration Headache Centers of Excellence Prior to and During the COVID-19 Pandemic: A Mixed Methods Study
Amy Grinberg, PhD

The Psychologists’ Role in Pediatric and Adult Headache Care: A Qualitative Analysis with Seven Experts
Amy Grinberg, PhD

Experiences of an Academic Headache Center with Telehealth for Headache Pain Psychology Treatment During the Covid-19 Pandemic
Susan Axtell, PsyD

Stroke risk in perimenopausal women with migraine
Crystal Sosa, MD
Other Clinical Studies

Efficacy and Safety of Intravenous Sodium Valproate in Pediatric Patients with Refractory Chronic Headache Disorders: A Retrospective Review

Crowdsourcing Post-marketing Safety Surveillance for Migraine Preventives: Self-reported Adverse Events Associated with Calcitonin Gene-related Peptide (CGRP) Therapeutics on a Social Media Forum
*Not CME Eligible

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Coadministered with Esomeprazole Magnesium
*Not CME Eligible

A Novel Approach to Defining Success in the Acute Treatment of Migraine: Pooled Results from the ACHIEVE I and ACHIEVE II Trials
*Not CME Eligible

A Novel Approach to Defining Success in the Acute Treatment of Migraine: Pooled Results from the ACHIEVE I and ACHIEVE II Trials

Ubrogepant Was Safe and Well Tolerated in the Acute Treatment of Perimenstrual Migraine

Essential Oils and Cluster Headache: Insights from Two Cases

A Novel Approach to Defining Success in the Acute Treatment of Migraine: Demonstrating Therapeutic Benefit at 1 Hour Post-dose in the Pooled ACHIEVE I and ACHIEVE II Trials
*Not CME Eligible

Long-term Safety and Tolerability of Atogepant Following Once Daily Dosing over 1 Year for the Preventive Treatment of Migraine
*Not CME Eligible

Atogepant 60 Mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results from a 52-Week Open-Label Extension Trial
*Not CME Eligible

Chronic Migraine and Alimentation During COVID-19 Lockdown

"Migraine Burden Index": A New Instrument for Assessing Migraine-Related Clinical Disability
*Not CME Eligible

Prodromal and Postdromal Symptoms in Primary Headaches. PREMECEF Results

Melatonin for Pediatric Migraine Prevention

Exercised Brain in Pain, Quantification of Exercise in Migraine Patients Seen at a Large Tertiary Headache Center

Napping and headache outcomes in adults with episodic migraine: a six-week prospective cohort study

Therapeutics

The Outpatient Pharmacologic Management of Status Migrainosus in Adults: Systematic Review and Expert Opinion, a Need of the Hour


Retrospective Study of Intranasal Ketamine for Use in Patients with Refractory Headache
Hsiangkuo Yuan, MD, PhD

Pharmacokinetic and Pharmacodynamic Variability of Triptans: A Review and Some Clinical Implications*
Peer Tfelt-Hansen, MD, DMSc

Monthly Migraine Days, Tablet Utilization, and Quality of Life Associated with Rimegepant – Post Hoc Results from an Open Label Safety Study (BHV3000-201)
Karissa Johnston, PhD

Rimegepant versus Atogepant and Monoclonal Antibody Treatments for the Prevention of Migraine: A Systematic Literature Review and Network Meta-analysis
Evan Popoff, MSc

Acute Treatment with Rimegepant 75 Mg Confers Long Term Improvements in Median Time to 30% and 50% Reductions in Monthly Migraine Days – Post Hoc Results from an Open Label Safety Study (BHV3000-201)*
Lauren Powell, MPH

Preference for Rimegepant and Improved Clinical Global Impression of Change Among Adults with a History of Triptan Treatment Failure: Results from a Long-Term Open-Label Safety Study
Ira Turner, MD

Rapid Decrease in Migraine Days with Rimegepant: Results from a Post Hoc Analysis of a Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Trial*
Richard Lipton, MD

Concordance of Response to Triptan with CGRP Monoclonal Antibody and Gepant: A Retrospective Review
Loretta Mueller, DO

Use of Memantine as a Preventative in Adolescents with Chronic Headache Disorders*
Deanna Duggan, DNP

Gepant Efficacy When Combined with a CGRP Monoclonal Antibody: A Retrospective Chart Review
Loretta Mueller, DO

Acute Treatment with Oral Rimegepant 75 Mg Reduces Migraine-Related Disability in Adults with and Without a History of Triptan Treatment Failure: Results from a One Year, Open-Label Safety Study* 
Richard Lipton, MD

Acute Treatment of Migraine with Rimegepant Improves Health Related Quality of Life in Adults with a History of Triptan Treatment Failure: Results from a Long-Term, Open-Label Safety Study
Ira Turner, MD

Occipital Nerve Blockade for the Treatment of Primary Headaches and Cranial Neuralgias*
Luis Fernández-Garza

CGRP Monoclonal Antibodies Along with CGRP Receptor Antagonists Are Safe and Effective Together and Compared to Standard of Care Safety and Efficacy of Repetitive Dihydroergotamine Infusion for the Acute Treatment of Refractory Chronic Migraine in Hospitalized Patients with Vascular Risk Factors
Amir Soheil Tolebeyan, MD

Treatment of Persistent Post-traumatic Headache with OnabotulinumtoxinA: Response Rates According to Clinical Phenotype*
Clint Lauritsen, DO

Comparative Efficacy of AXS-07 (MoSEIC™ Meloxicam/Rizatriptan) versus Rizatriptan in the Acute Treatment of Migraine*
Allison Koutsandreas, CANP

Cedric O’Gorman, MD
<table>
<thead>
<tr>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sustained, Clinically Meaningful Responses to Fremanezumab Treatment in Migraine Patients with Inadequate Response to 2-4 Prior Classes of Migraine Preventive Medications</td>
<td>Carrie Dougherty, MD, FAHS</td>
</tr>
<tr>
<td>Effects of Discontinuing Erenumab Treatment in Patients with High-frequency Episodic Migraine and Chronic Migraine: Experience of a Third-level Headache Center</td>
<td>Massimo Autunno</td>
</tr>
<tr>
<td>Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses from 3 Phase 3 Clinical Trials by Number of Triptans Previously Tried and Failed*</td>
<td>Richard Lipton, MD</td>
</tr>
<tr>
<td><em>Not CME Eligible Treatment of Migraine Pain and Associated Symptoms with AXS-07: Results from MOVEMENT, a Long-term Efficacy and Safety Study</em></td>
<td>Amanda Jones, PharmD</td>
</tr>
<tr>
<td>*Not CME Eligible Clinically Meaningful Responses to Fremanezumab Treatment in Episodic and Chronic Migraine over up to 15 Months</td>
<td>Stephanie Nahas, MD, MSEd, FAHS</td>
</tr>
<tr>
<td>No Evidence of Wearing off Effect for Fremanezumab Treatment in Chronic and Episodic Migraine Patients with Inadequate Response to 2-4 Prior Classes of Migraine Preventive Medications</td>
<td>Amaal Starling, MD</td>
</tr>
<tr>
<td>Real-world Reductions in Migraine and Headache Days After Initiating Fremanezumab for US Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway*</td>
<td>Maurice Driessen, PhD</td>
</tr>
<tr>
<td><em>Not CME Eligible Reduced Nausea When Dihydroergotamine Mesylate Is Delivered by INP104</em></td>
<td>Stephen Shrewsbury, MD</td>
</tr>
<tr>
<td><em>Not CME Eligible DHE Pharmacology Revisited: Does a Broad Receptor Profile Molecule Treat the Whole Migraine?</em></td>
<td>Sheena K Aurora, MD</td>
</tr>
<tr>
<td>*Not CME Eligible Combining Remote Electrical Neuromodulation (REN) with Guided Intervention of Education and Relaxation (GIER) in the Acute Treatment of Migraine</td>
<td>Dawn Buse, PhD</td>
</tr>
<tr>
<td>Efficacy of Lasmiditan for the Acute Treatment of Perimenstrual Migraine</td>
<td>E. Anne MacGregor, MBBS, MSc, MD, FFSRH</td>
</tr>
<tr>
<td>Comparison of Remote Electrical Neuromodulation (REN) and Standard-care Medications for Acute Treatment of Migraine in Adolescents: A Post-hoc Analysis</td>
<td>Andrew Hershey, MD, PhD, FAHS</td>
</tr>
<tr>
<td>Effects of Erenumab on Non-pain Symptoms in Patients with Chronic Migraine</td>
<td>Stewart Tepper, MD</td>
</tr>
<tr>
<td>Real Life Experience with Galcanezumab in a Single Tertiary Headache Center</td>
<td>Victor Obach, MD</td>
</tr>
<tr>
<td>Neuroscience Education as Therapy for Migraine and Overlapping Pain Conditions*</td>
<td>Mia Minen, MD, MPH</td>
</tr>
<tr>
<td>*Not CME Eligible Long-term Use of Rimegepant 75 Mg for the Acute Treatment of Migraine Reduces Use of Analgesics and Antiemetics</td>
<td>David Kudrow, MD</td>
</tr>
<tr>
<td>Rimegepant 75 Mg for the Acute Treatment of Migraine in Adults with Frequent Migraine: Long-Term Safety and Clinical Improvement versus Baseline</td>
<td>Kathleen Mullin, MD</td>
</tr>
<tr>
<td>*Not CME Eligible Long-Term Safety of Rimegepant 75 Mg for the Acute Treatment of Migraine in Adults with a History of Triptan Treatment Failure</td>
<td>Kathleen Mullin, MD</td>
</tr>
</tbody>
</table>
Recurrence Rates for INP104 for the Acute Treatment of Migraine: Results from the Phase 3 STOP 301 Open-Label Study

Stewart Tepper, MD

Acute Treatment of Migraine with INP104: Exploratory Efficacy from the Phase 3 Open-Label STOP 301 Study*

Sheena Aurora, MD

Cardiovascular Safety Results of INP104 (POD-DHE) from the STOP 301 Phase 3 Study*

Stephen Shrewsbury, MD

Nasal Safety of Chronic Intermittent Use of INP104: Results from the Phase 3 Open-Label STOP 301 Study*

Stephen Shrewsbury, MD

Treatment Consistency Across Multiple Migraine Attacks: Results from the Phase 3 Open-Label STOP 301 Study*

Richard Lipton, MD

Daily Atogepant Provides a Rapid Onset and Sustained Benefit in the Preventive Treatment of Migraine*

Todd Schwedt, MD

Reduction in Migraine-Associated Burden After Eptinezumab Treatment in Patients with Chronic Migraine

Peter McAllister, MD

Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days*

Lawrence Severt, MD, PhD

Efficacy and Safety of Erenumab in Patients with Episodic Migraine in East Asia: Taiwan and Korea Subpopulation Analysis of the EMPOwER Study

Richard B. Lipton, MD

Ubrokeptant Treatment When Pain Is Mild Increases the Likelihood of Achieving Pain Freedom in Participants Who Treated Migraine Attacks of Mild and Moderate or Severe Pain*

Shuu-Jiun Wang, MD

Consucutive Headache-Free Days with OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: A Pooled PREEMPT Analysis*

Katherine Sommer, PhD

Real-World Evidence for Control of Chronic Migraine in Patients Meeting American Headache Society Criteria Who Received Calcitonin Gene–Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA

Andrew Blumenfeld, MD

Lasmigapant: A Case Report of Simultaneous Administration of Lasmiditan and Rimegepant

Paul Mathew, MD, NDBPAS, FAHS

A Randomized Controlled Trial of High Rate rTMS versus rTMS and Amitriptyline in Chronic Migraine

Jayantee Kalita, DM

Analysis of Nutraceutical Medications for Migraine Prevention in a Pediatric and Adolescent Headache Clinic Population

Irene Patniyot, MD

Selection Drivers for Recently Prescribed Lasmiditan, Ubrokeptant, or Rimegepant for the Acute Treatment of Migraine: Results from an Annual Cross-Sectional Patient Chart Audit in the United States

Virginia Schobel, MSc

Evaluation of the Correlations Between Pretreatment Plasma CGRP Levels, Disease Characteristics and Fremanezumab Treatment Response in Patients with Posttraumatic Headache*

Jacki Rorabaugh, PhD
Patients with Migraine Who Achieved a ≥75% Reduction in Monthly Migraine Days with Eptinezumab Treatment: Subgroup Analysis of PROMISE-1 and PROMISE-2*  
*Not CME Eligible
Richard B. Lipton, MD

Eptinezumab for Migraine Prevention in Patients 50 Years or Older: A Subgroup Analysis of PROMISE-1 and PROMISE-2
Vincent Martin, MD

Efficacy and Safety of Eptinezumab in Patients with Migraine and Self-Reported Aura: Post Hoc Analysis PROMISE-1 and PROMISE-2*  
*Not CME Eligible
Messoud Ashina, MD, PhD, DMSc

Early Response to Eptinezumab Indicates High Likelihood of Continued Response with Treatment in Patients with Chronic Migraine*  
*Not CME Eligible
Dawn Buse, PhD

Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients with Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2  
*Not CME Eligible
Vincent Martin, MD

Changes in Blood Pressure Category with Erenumab: A Pooled Analysis of Phase 2 and Phase 3 Clinical Trials*  
*Not CME Eligible
David Dodick, MD

Daily Dosing of Atogepant for Preventive Treatment of Migraine Improved Patient-Reported Outcomes Measures of Migraine-Specific Quality of Life, Activity Impairment in Migraine-Diary, and Headache-Impact Test in a 52-Week Trial*  
*Not CME Eligible
Pranav Gandhi, PhD

Cardiovascular Safety of Eptinezumab: A Pooled Analysis of Double-Blind, Randomized, Placebo-Controlled Studies*  
*Not CME Eligible
Timothy R. Smith, MD, RPh

Evaluation of Ischemic Cardiovascular and Cerebrovascular Adverse Events by 10-year Cardiovascular Risk Score in Patients with Migraine Treated with Erenumab*  
*Not CME Eligible
David Kudrow, MD

Consistent Efficacy and Safety of Erenumab over Time in Patients with Episodic Migraine Who Completed a 5-year, Open-label Extension Study*  
*Not CME Eligible
Messoud Ashina, MD, PhD, DMSc

Utilization of Dihydroergotamine in Emergency Department and Infusion Center for Pediatric Migraine: A Retrospective Study  
*Not CME Eligible
Ankita Ghosh, MD

Non-invasive Vagus Nerve Stimulation for Visual Snow*  
*Not CME Eligible
Karissa Arca, MD

Galcanezumab Effective for Chronic Refractory Cluster Headaches: A Case Report  
*Not CME Eligible
Golshan Fahimi, MD

Real World Efficacy, Tolerability and Safety of Ubrogepant  
Effect of Strong P-gp and BCRP Inhibition, Using Cyclosporine and Quinidine as Probes, on the Pharmacokinetics of Oral Rimegepant 75 mg in Healthy Subjects*  
*Not CME Eligible
Chia-Chun Chiang, MD

Erenumab Versus Topiramate for the Prevention of Migraine: Results of a Randomized Active-controlled Double-dummy Trial*  
*Not CME Eligible
Richard Bertz, PhD

Improvement in Migraine Disability from Mindfulness is Mediated by Improvements in Pain Catastrophizing and Depression  
*Not CME Eligible
Rebecca Wells, MD, MPH

Mechanisms of Mindfulness Through the Lens of Patient Voices: Results of a Qualitative Study  
*Not CME Eligible
Rebecca Wells, MD, MPH
Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine*
*Not CME Eligible
Laszlo Mechtler, MD

Relative Efficacy of Lasmiditan versus Rimegepant and Ubrogepant as Acute Treatments of Migraine: Network Meta-Analysis Findings on Early Onset of Efficacy*
*Not CME Eligible
Pepa Polavieja, MSc